Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Triplet Therapy With Selinexor Tested in Myeloma

Ariela Katz
Published: Monday, Dec 04, 2017
Sundar Jagannath, MBBS

Sundar Jagannath, MBBS
Selinexor (KPT-330), a novel drug that targets a tumor-suppressor “cargo” protein mechanism, is being investigated in patients with relapsed/refractory multiple myeloma (MM) who have received 1 to 3 prior treatment regimens. The BOSTON trial, which is currently enrolling participants, is seeking to assess the safety of selinexor in combination with standard-of-care treatment including a proteasome inhibitor and a glucocorticoid.

The small molecule is being administered in combination with bortezomib (Velcade) and dexamethasone in the phase III BOSTON trial (NCT03110562). Eligible patients will have documented evidence of relapsed/refractory MM after at least 1 treatment regimen but no more than 3 prior regimens, which may include bortezomib or another proteasome inhibitor. Participants must also have no central nervous system involvement.

The multicenter international trial will randomize an estimated 350 adult participants to receive either the 3 drugs in combination or bortezomib and dexamethasone alone (Figure). The primary endpoints are progression-free survival and overall response rate (ORR). Notably, patients who have progressive disease while on bortezomib and dexamethasone will have the option to cross over to the experimental arm to be treated with selinexor.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication